News

Astellas publish its Integrate Report（former Annual Report) to enable deeper stakeholder understanding of Astellas' efforts to continuously create VALUE for sustainable growth. Integrated Report 2022 is now available at the following link: https://www.astellas.com/en/system/files/astellas_ir2022_en_20220930.pdf

TOKYO, September 30, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the European Medicines Agency (EMA) has accepted for regulatory review the company’s marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms...

TOKYO, September 26, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) confirms the U.S. District Court for the District of Delaware’s order granting an interim injunction enjoining Hospira from launching its generic version of LEXISCAN® until October 5, 2022. The District Court, however, denied Astellas’ request for a Preliminary Injunction while...

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab – – Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 – TOKYO, BOTHELL, Wash. and RAHWAY, N.J. -- September 12, 2022 -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji...

Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...